Please wait a minute...
浙江大学学报(医学版)  2016, Vol. 45 Issue (3): 256-260    DOI: 10.3785/j.issn.1008-9292.2016.05.06
艾滋病专题     
人类免疫缺陷病毒储存库评估测定技术研究进展
周琦惠, 朱彪
浙江大学医学院附属第一医院感染病中心 传染病诊治国家重点实验室 感染病诊治协同 创新中心, 浙江 杭州 310003
Research advances in evaluation and measurement techniques of latent human immunodeficiency virus reservoirs
ZHOU Qihui, ZHU Biao
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
全文: PDF(966 KB)  
摘要: 

HIV整合至CD4+T细胞、脾脏、淋巴结、胃肠相关淋巴组织中,成为HIV潜伏感染的储存库。学界提出“shock and kill”的治疗策略,即先激活释放再杀灭病毒。而实施该策略的前提是评估和测定HIV储存库的大小。本文介绍目前常用的测定HIV储存库方法如Alu-gag PCR、定量病毒产物分析及tat/rev诱导有限稀释法。Alu-gag PCR可区别整合与未整合病毒基因,但不能区分缺陷与有功能的前病毒,因此易高估储存库。定量病毒产物分析在纯化静止CD4+T细胞中进行,被誉为HIV储存库检测的“金标准”,但实验成本高,技术要求高,所需标本量大,仅由一轮激活并不能完全诱导产物释放,因此会低估储存库。Tat/rev诱导有限稀释法主要测定经由刺激物诱导表达多拼接RNA等生物学标志的潜伏感染细胞频数,具有所需血标本少,不用抽提病毒RNA,实验时间短,对于不同大小储存库都适用等优点,但可能高估潜伏储存库。

关键词 HIV聚合酶链反应基因产物,tat基因,调节综述    
Abstract

Latent reservoir (LR) of HIV is the cells (such as CD4+T cell) where HIV is able to hide. These cellular reservoirs are located throughout the body, including the spleen, lymph nodes, gastrointestinal lymphoid tissues, and become the major obstacle to cure HIV infection. To truly cure patients, a new strategy "shock and kill" was put forward by scientists, which is to shock HIV-infected cells out of hidden reservoirs in the body and then kill them. Quantitatively evaluating the size of long-lived LR is essential to this strategy. This paper reviews assays that measure the magnitude of the latent HIV reservoir, including Alu-gag PCR, quantitative viral outgrowth assay (Q-VOA) and tat/rev induced limiting dilution assay(TILDA). Alu-gag PCR can differentiate the integrated and un-integrated HIV DNA, however, it cannot distinguish defective virus from competent virus, leading to overestimate the real size of LR. Q-VOA is based on cell culture, and is the golden standard for measuring the LR since it provides a definitive minimal estimate of reservoir size. Its disadvantages are being more costly, large amount of blood sample required, and underestimating the true size, which was resulted from particles being not released after one round of stimulation. TILDA measures cells with inducible msRNA as these transcripts are absent in latently infected cells but induced upon viral reactivation. It requires small blood sample size, does not need extraction of viral nucleic acids, can be completed in 2 d and covers a wide dynamic range of reservoir sizes, but has the disadvantage of overestimating the true size of LR.

Key wordsHIV    Polymerase chain reaction    Gene products, tat    Genes, regulator    Review
收稿日期: 2016-03-29
CLC:  R512.91  
基金资助:

“十二五”艾滋病和病毒性肝炎等重大传染病防治科技重大专项(2013ZX10001004-002-003,2014ZX10001002-002-002)

通讯作者: 朱彪(1965-),男,博士,主任医师,硕士生导师,从事艾滋病及相关疾病的研究;E-mail:zhubiao1207@zju.edu.cn;http://orcid.org/0000-0001-8423-2447     E-mail: zhubiao1327@zju.edu.cn
作者简介: 周琦惠(1991-),女,硕士研究生,从事艾滋病功能性治愈研究;E-mail:zhouqihui1991@126.com;http://orcid.org/0000-0001-5369-3320
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  

引用本文:

周琦惠 等. 人类免疫缺陷病毒储存库评估测定技术研究进展[J]. 浙江大学学报(医学版), 2016, 45(3): 256-260.
ZHOU Qihui, ZHU Biao. Research advances in evaluation and measurement techniques of latent human immunodeficiency virus reservoirs. Journal of ZheJiang University(Medical Science), 2016, 45(3): 256-260.

链接本文:

http://www.zjujournals.com/xueshu/med/CN/10.3785/j.issn.1008-9292.2016.05.06      或      http://www.zjujournals.com/xueshu/med/CN/Y2016/V45/I3/256

[1] DAHL V, JOSEFSSON L, PALMER S. HIV reservoirs, latency, and reactivation: prospects for eradication[J]. Antiviral Res, 2010, 85(1): 286-294.
[2] LAIRD G M, EISELE E E, RABI S A, et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay[J/OL]. PLoS Pathog, 2013, 9(5): e1003398.
[3] BRUNER K M, HOSMANE N N, SILICIANO R F. Towards an HIV-1 cure: measuring the latent reservoir[J]. Trends Microbiol, 2015, 23(4): 192-203.
[4] BAROUCH D H, DEEKS S G. Immunologic strategies for HIV-1 remission and eradication[J]. Science, 2014, 345(6193): 169-174.
[5] SHAN L, SILICIANO R F. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication[J]. Bioessays, 2013, 35(6): 544-552.
[6] LISZEWSKI M K, YU J J, O'DOHERTY U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR[J]. Methods, 2009, 47(4): 254-260.
[7] AGOSTO L M, LISZEWSKI M K, MEXAS A, et al. Patients on HAART often have an excess of unintegrated HIV DNA: implications for monitoring reservoirs[J]. Virology, 2011, 409(1):46-53.
[8] O'DOHERTY U, SWIGGARD W J, JEYAKUMAR D, et al. A sensitive, quantitative assay for human immunodeficiency virus type 1 integration[J]. J Virol, 2002, 76(21): 10942-10950.
[9] HAN Y, ROTOLO M W, YANG H C, et al. Experimental approaches to the study of HIV-1 latency[J]. Nat Rev Microbiol, 2007, 5(2): 95-106.
[10] BARTON K M, PALMER S E. How to define the latent reservoir:tools of the trade[J].Curr HIV/AIDS Rep, 2016, 13(2): 77-84.
[11] ARCHIN N M, SUNG J M, GARRIDO C, et al. Eradicating HIV-1 infection: seeking to clear a persistent pathogen[J]. Nat Rev Microbiol, 2014, 12(11): 750-764.
[12] PROCOPIO F A, FROMENTIN R, KULPA D A, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals[J]. EBioMedicine, 2015, 2(8): 874-883.
[13] PASTERNAK A O, LUKASHOV V V, BERKHOUTB. Cell-associated HIV RNA: a dynamic biomarker of viral persistence[J]. Retrovirology, 2013, 10:41.
[14] ALIDJINOU E K, BOCKET L, HOBER D. Quantification of viral DNA during HIV-1 infection: a review of relevant clinical uses and laboratory methods[J]. Pathol Biol (Paris), 2015, 63(1):53-59.
[15] KISELINOVA M, SPIEGELAERE W D, BUZON M J, et al. Integrated and total HIV-1 DNA predict ex vivo viral outgrowth[J/OL]. PLoS Pathog, 2016, 12(3): e1005472.
[16] CHUN T W, CARRUTH L, FINZI D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection[J]. Nature, 1997, 387(6629): 183-188.
[17] TYAGI M, BUKRINSKY M. Human immunodeficiency virus (HIV) latency: the major hurdle in hiv eradication[J]. Mol Med, 2012, 18: 1096-1108.
[18] CHUN T W, MOIR S, FAUCI A S. HIV reservoirs as obstacles and opportunities for an HIV cure[J]. Nat Immunol, 2015, 16(6): 584-589.
[19] ROUZIOUX C, RICHMAN D. How to best measure HIV reservoirs?[J]. Curr Opin HIV AIDS, 2013, 8(3): 170-175.
[1] 郑艳榕,张翔南,陈忠. Nix介导的线粒体自噬机制的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 92-96.
[2] 李文龙,瞿海斌. 近红外光谱应用于中药质量控制及生产过程监控的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 80-88.
[3] 高思倩,沈咏梅,耿福能,李艳华,高建青. 糖尿病溃疡动物模型的建立及相关治疗研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 97-105.
[4] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报(医学版), 2017, 46(1): 15-21.
[5] 高思倩,沈咏梅,耿福能,李艳华,高建青. 颞叶癫痫与海马成体神经再生[J]. 浙江大学学报(医学版), 2017, 46(1): 97-105.
[6] 封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报(医学版), 2016, 45(6): 655-660.
[7] 李统宇 等. 杜氏肌营养不良疾病模型及基因治疗研究进展[J]. 浙江大学学报(医学版), 2016, 45(6): 648-654.
[8] 曹鹏 等. 双氢青蒿素抗肿瘤分子生物学机制研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 501-507.
[9] 吴志华 等. 异基因造血干细胞移植受者T细胞受体β链CDR3谱型表达与巨细胞病毒激活[J]. 浙江大学学报(医学版), 2016, 45(5): 515-521.
[10] 李亭亭 等. 中性粒细胞在哮喘中作用的研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 544-549.
[11] 王雪 等. TANK结合激酶1在抗病毒免疫应答中的作用研究进展[J]. 浙江大学学报(医学版), 2016, 45(5): 550-557.
[12] 杜苗苗 等. 钙化性主动脉瓣疾病药物治疗研究进展[J]. 浙江大学学报(医学版), 2016, 45(4): 432-438.
[13] 陈晓静 等. 微RNA-let-7e-3p在宫颈上皮内瘤变和宫颈癌组织中的表达及临床意义[J]. 浙江大学学报(医学版), 2016, 45(4): 342-348.
[14] 何斌 等. 贝伐珠单克隆抗体在难治性子宫颈癌中的应用进展[J]. 浙江大学学报(医学版), 2016, 45(4): 395-402.
[15] 历雪莹 等. DNA甲基化及其靶向治疗在急性髓系白血病中的研究进展[J]. 浙江大学学报(医学版), 2016, 45(4): 387-394.